A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
Learn more: New compound shows promise in treating multiple human cancers
The Latest on: Cancer treatment
[google_news title=”” keyword=”cancer treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer treatment
- Wheeling for Healing returns to South Deerfield to raise money for cancer treatmenton May 10, 2024 at 6:28 pm
After a successful move to Yankee Candle last year, the 17th annual Wheeling for Healing event is back on May 19, as the fundraiser seeks to continue raising tens of thousands of dollars for cancer ...
- Bristol Myers Squibb Cancer-Treatment Trial Misses Endpointon May 10, 2024 at 1:55 pm
Bristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint.
- Dogma-challenging telomere findings may offer new insights for cancer treatmentson May 10, 2024 at 11:39 am
A new study shows that an enzyme called PARP1 is involved in repair of telomeres, the lengths of DNA that protect the tips of chromosomes, and that impairing this process can lead to telomere ...
- Standard blood cancer treatment reveals positive results in those over 80, study findson May 10, 2024 at 1:11 am
The standard treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, a study published Thursday in Blood Neoplasia finds. The treatment can extend survival for about 25% ...
- Racial, ethnic differences seen in breast cancer treatment declinationon May 9, 2024 at 4:59 pm
For patients with breast cancer, there are racial and ethnic differences in treatment declination, according to a study published online May 9 in JAMA Network Open. Data were included from 2,837,446 ...
- The doctor behind the next big thing in cancer treatmenton May 9, 2024 at 10:36 am
Dr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines that are tailored to the genetic makeup of an individual’s tumor. It’s a strategy that is looking ...
- King Charles Takes on First Solo Engagement Since Returning to Royal Duties During Cancer Treatmenton May 9, 2024 at 5:46 am
King Charles made his first solo engagement since resuming royal duties amid his cancer treatment. The monarch met with the families and staff at the Royal School of Military Engineering.
- Matching Cancer Patients To Trials And Treatments With Triomicson May 9, 2024 at 5:00 am
Triomics has raised $15 million of funding as it moves to commercialise its AI platform for oncologists, hospitals and healthcare providers ...
- I Had Cancer. My Treatment Was Eye-Opening About Addictionon May 9, 2024 at 1:30 am
I've had two different types of cancer in two years and in both instances, I was screened, diagnosed early, and ushered into care.
via Bing News